FDA Approves Oral Treatment for CSU

Remibrutinib is the first Bruton tyrosine kinase inhibitor approved by the FDA for chronic spontaneous urticaria.
Medscape Medical News

Source link : https://www.medscape.com/viewarticle/fda-approves-oral-btk-inhibitor-chronic-spontaneous-2025a1000q9c?src=rss

Author :

Publish date : 2025-10-01 07:09:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

FDA Approves Oral Treatment for CSU

How Do Cancer Survivors Fare After Lung Cancer Screening?

Ultraprocessed Foods Strongly Linked to Elevated MS Activity

Related Posts

‘More Training to Earn Less’: The Ped Subspecialist Shortage

Jeffrey Epstein’s Crimes: Child Sexual Abuse Isn’t a ‘Type’

RFK Jr. Was ‘Nauseous’ About Endorsing Trump, Alleged Ex-Lover Says

Lockdown could have been avoided and other key findings

CDC Website No Longer Rejects Autism-Vaccine Link

Doc Faces Extradition to Japan; ‘Missing Ketamine’ Arrest; Cancer Drugs Diverted

‘More Training to Earn Less’: The Ped Subspecialist Shortage

Jeffrey Epstein’s Crimes: Child Sexual Abuse Isn’t a ‘Type’

RFK Jr. Was ‘Nauseous’ About Endorsing Trump, Alleged Ex-Lover Says

Lockdown could have been avoided and other key findings

CDC Website No Longer Rejects Autism-Vaccine Link

Doc Faces Extradition to Japan; ‘Missing Ketamine’ Arrest; Cancer Drugs Diverted

NICE Backs Five AI Tools for Bowel Cancer Detection

Taking HBV Vaccines to Migrants Boosts Acceptance

Categories

Archives